REAL PCTAPTC 02 MAR 2005

PATENT COOPERATION TREATY

REC'D	24	JAN	2005	
WIPO		p	CT	-

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference					
MTX_102	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)			
International application No.	International filing date (day/month	/year)	Priority Date (day/month/year)		
PCT/IN 2003/000294 2 September 2003 (02.09.2003)		2 September 2002 (02.09.2002)			
International Patent Classification (IPC) or nat	International Patent Classification (IPC) or national classification and IPC				
IPC ⁷ : A61K 31/421, 9/14, 45/06					
Applicant					
SUN PHARMACEUTICAL INDUS	TRIES LIMITED				
This international preliminary exar and is transmitted to the applicant and its transmitted to the applicant and applicant and applicant are applicant.	nination report has been prepared according to Article 36.	d by this I	nternational Preliminary Examination Authority		
2. This REPORT consists of a total or	f <u>6</u> sheets, including t	his cover	sheet.		
amended and are the basis for	This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).				
These annexes consist of a total of	sheets.				
3. This report contains indications rela	ating to the following items:	-			
I. Basis of the opini					
II. Priority	II. Priority				
III. Non-establishmen	III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
IV. Lack of unity of i	nvention				
V. Reasoned stateme citations and expl	V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
VI. Certain document	s cited				
VII. Certain defects in	n the international application				
VIII. Certain observations on the international application					
Date of submission of the demand Date of completion of this report			on of this report		
08.03.2004 3 January 2005 (03.01.2005)					
Name and mailing address of the IPEA/AT	Name and mailing address of the IPEA/AT Authorized officer				
Austrian Patent Office					
Dresdner Straße 87			KRENN M.		
A-1200 Vienna					
Facsimile No. 1/53424/200 Telephone No. 1/53424/435					
Form PCT/IPEA/409 (cover sheet) (July 1998)					

International application No.
PCT/IN 2003/000294

I.		Basis of the report
1.	Wi	th regard to the elements of the international application:*
	\boxtimes	the international application as originally filed
		the description:
		pages, as originally filed
ĺ		pages, filed with the demand
	_	pages, filed with the letter of
	Ш	the claims:
		pages, as originally filed
		pages, as amended (together with any statement) under Article 19 pages, filed with the demand
		pages, filed with the letter of
•		the drawings:
	ш	pages, as originally filed
		pages, filed with the demand
		pages, filed with the letter of
		the sequence listing part of the description:
		pages, as originally filed
		pages, filed with the demand
		pages, filed with the letter of
2.	Witl	h regard to the language, all the elements marked above were available or furnished to this Authority in the language in
	*****	ch the international application was filed, unless otherwise indicated under this item. se elements were available or furnished to this Authority in the following language which is:
		the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
		the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international application (under Rule 48.3(b)).
		the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).
3.	With preli	n regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international minary examination was carried out on the basis of the sequence listing:
		contained in the international application in printed form.
		filed together with the international application in computer readable form.
		furnished subsequently to this Authority in written form.
		furnished subsequently to this Authority in computer readable form.
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
	Ш	The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4.		The amendments have resulted in the cancellation of:
		the description, pages
		the claims, Nos
		the drawings, sheets/fig
5.	<u> </u>	This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
	eplac this : 0.17).	ement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to report as "originally filed" and are not annexed to this report since they do not contain under Article 14 are referred to
		placement sheet containing such amendments must be referred to under item 1 and annexed to this report.
Forn	PCT	(IPEA/409 (Box I) (July 1998))

International application No. PCT/IN 2003/000294

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	
1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to industrially applicable have not been examined in respect of:	o be
the entire international application,	
Claims Nos. 19-22,25,26.	
because: the said international application, or the said claims Nos. require an international preliminary examination (specify):	es not
the description, claims or drawings (indicate particular elements below) or said claims Nos. 19-22,25,26 are unclear that no meaningful opinion could be formed (specify): Characterization of pharmaceutical dosage forms by their modes of administratis insufficient; thus claims 19-22 resp. the dependent claims 25 and 26 were not considered in optoblishing the property.	_4'
considered in establishing the present examination.	
the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.	on
no international search report has been established for said claims Nos.	
A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amir sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions: the written form has not been furnished or does not comply with the standard.	o acid
the computer readable form has not been furnished or does not comply with the standard. m PCT/PEA/409 (Box III) (July 1998)	

International application No. PCT/IN 2003/000294

V. Reasoned statement under Art citations and explanations sup	ticle 35(2) porting si	with regard to novelty, inventive step or industrial applicability; uch statement	 -
1. Statement			
Novelty (N)	Claims	8-14	YES
	Claims	1-7,15-18,23,24	NO
Inventive step (IS)	Claims		YES
	Claims	1-18,23,24	NO
Industrial applicability (IA)	Claims	1-18,23,24	YES
	Claims	*****	NO
Citations and explanations (Rule 70.	7)		

As the applicant has abstained from responding to the Written Opinion, the objections raised therein are still maintained.

Consequently, only claims 8-14 show the required novelty, whereas claims 1-7,15-18,23 and 24 are not considered to be new.

Inventiveness is denied for all examined claims, namely claims 1-18,23 and 24.

Industrial applicability is given for claims 1-18,23 and 24.

International application No. PCT/IN 2003/000294

VI.	Certain documents cited			
1.	Certain published documents (Rule 7	0.10)		
	Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim)(day/month/year)
	DE 10153078 A1	22.5.2003	30.10.2001	
2.	Non-written disclosures (Rule 70.9)			
	Kind of non-written disclosure	Date of non-wri	tten disclosure n/year)	Date of written disclosure referring to non-written disclosure (day/month/year)
Form	PCT/IDEA/400 (D- VY) /7 1 1000			
Form	PCT/IPEA/409 (Box VI) (July 1998)			

Form PCT/IPEA/409 (Box VII) (July 1998)

International application No. PCT/IN 2003/000294

VII.	Certain defects in the international application			
The follo	owing defects in the form or contents of the international application have been	n noted:		
"pha pharm	The characterizing parts of claims 1,2,5 and 8 were not considered in establishing the present report, because they include insufficiently defined formulations, namely "pharmaceutical composition has enhanced oral bioavailability." (claims 1,8), "a pharmaceutically acceptable solubility-improved form." (claim 2) and "high-energy crystalline form of metaxalone." (claim 5).			